Incyte

Tallac Therapeutics Appoints Kevin N. Heller, M.D., as Chief Medical Officer

Retrieved on: 
Thursday, January 19, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, National university, Immunology, TRAAC, Memorial Sloan Kettering Cancer Center, Evaluation, Biochemistry, Therapy, Immunotherapy, Incyte, Faculty, Rockefeller University, AstraZeneca, Pediatrics, Patient, Jasper, Yale University, George Washington University, Cancer, Clinical trial, BMS, Multimedia, TLR9, Pulsus Group, Bristol Myers Squibb, Pharmaceutical industry, Tallac Records

Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced the appointment of Kevin N. Heller, M.D., as chief medical officer.

Key Points: 
  • Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced the appointment of Kevin N. Heller, M.D., as chief medical officer.
  • View the full release here: https://www.businesswire.com/news/home/20230119005166/en/
    Tallac Therapeutics Appoints Kevin N. Heller, M.D., as Chief Medical Officer (Graphic: Business Wire)
    “We are especially pleased to welcome Kevin to Tallac’s leadership team at a time when the Company is advancing novel immunotherapeutic agents in early clinical development,” said Hong I. Wan, Ph.D., president, CEO and co-founder of Tallac Therapeutics.
  • “Kevin brings a wealth of expertise as a seasoned drug developer with a proven track record of clinical trial planning and execution.
  • Prior to that, he was chief medical officer at NextCure, Inc., a biotechnology company developing immunotherapy-based biologics for cancer and other diseases.

Mr. David Gryska Appointed to Forte Biosciences Board of Directors

Retrieved on: 
Thursday, January 12, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Bristol Myers Squibb, Aerie Pharmaceuticals, Biotechnology, Senior, Celgene, Paul, Acquisition, GW Pharmaceuticals, Management, Incyte

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), announced today that Mr. David Gryska has been appointed to the Forte Biosciences Board of Directors.

Key Points: 
  • Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), announced today that Mr. David Gryska has been appointed to the Forte Biosciences Board of Directors.
  • Mr. Gryska was previously the Chief Financial Officer and Executive Vice President at Incyte.
  • Prior to joining Incyte, Mr. Gryska held the position of Chief Financial Officer and Senior Vice President at Celgene prior to its acquisition by Bristol-Myers Squibb.
  • Mr. Gryska commented, “I am very pleased to join Paul and the Board of Forte.

CORRECTING and REPLACING --Merus Provides 2023 Outlook

Retrieved on: 
Monday, January 9, 2023
Betta, Enzalutamide, NSCLC, Large-cell lung carcinoma, EAP, Prostate cancer, Lilly, Cancer, Incyte, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Trial of the century, General counsel, Eli Lilly and Company, Safety, FDA, Pancreatic cancer, Lung, Afatinib, Enrollment, NRG1, Food, BLA, Patient, HER3, Drug design, CD3, Abiraterone acetate, EGFR, Research, Castration, Clinical trial, Head, HER2, Satellite navigation device, Pharmaceutical industry, Medicine, HNSCC, CRPC, Meru Networks

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today provided its 2023 outlook.

Key Points: 
  • The corrected release follows:
    UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today provided its 2023 outlook.
  • “2023 looks to be another productive year for Merus with multiple value-creating clinical updates throughout the year.
  • Merus plans to provide an initial clinical data update on Zeno in CRPC in the second half of 2023.
  • Merus plans to provide a clinical update for petosemtamab at a medical conference in the first half of 2023.

EQS-News: MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability

Retrieved on: 
Sunday, January 22, 2023
SG, FSE, Patient, Medicine, NCCN, B-cell lymphoma, Royalty Pharma, Life insurance, Security (finance), Bank, Assurance services, Bookkeeping, Clothing, Music, Tafasitamab, Incyte, MorphoSys

MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability

Key Points: 
  • MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
    The issuer is solely responsible for the content of this announcement.
  • MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
    MorphoSys AG (FSE: MOR; NASDAQ: MOR) today reported preliminary Monjuvi® U.S. net product sales for the full year of 2022 and provided its financial guidance for 2023.
  • Preliminary Monjuvi (tafasitamab-cxix) U.S. net product sales are US$ 25.3 million (€ 24.0 million) for the fourth quarter and US$ 89.4 million (€ 84.9 million) for the full year of 2022.
  • For the full year of 2023, MorphoSys expects Monjuvi U.S. net product sales in the range of US$ 80 to 95 million.

Merus Provides 2023 Outlook

Retrieved on: 
Sunday, January 8, 2023
Eli Lilly and Company, General counsel, Prostate cancer, Cancer, Clinical trial, Head, Trial of the century, Food, Lung, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, Castration, BLA, Afatinib, Drug design, EAP, HER3, CD3, Incyte, Patient, NRG1, Safety, Enrollment, FDA, Large-cell lung carcinoma, HER2, Pancreatic cancer, NSCLC, Betta, Lilly, EGFR, Pharmaceutical industry, Medicine, Meru Networks, HNSCC, CRPC

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 08, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today provided its 2023 outlook.

Key Points: 
  • “2023 looks to be another productive year for Merus with multiple value-creating clinical updates throughout the year.
  • Merus plans to provide a clinical update on Zeno in NRG1+ cancer at a major medical conference in 2023.
  • Merus plans to provide an initial clinical data update on Zeno monotherapy in CRPC in the second half of 2023.
  • Merus plans to provide a clinical update for petosemtamab at a medical conference in the first half of 2023.

CURE Media Group announces winners of the 2022 MPN Heroes Recognition Program

Retrieved on: 
Friday, December 9, 2022
H. Lee Moffitt Cancer Center & Research Institute, Survivor, Pancreatic serous cystadenoma, Diagnosis, Leukemia, Motivation, Human, Therapy, PV, Lymphatic system, Polycythemia vera, Science, Cancer, Memorial Sloan Kettering Cancer Center, Radio, Knowledge, MPN, Education, Organization, Weill Cornell Medicine, Research, Social media, Caregiver, Patient, MD Anderson Cancer Center, Medical device, Medicine, Pharmaceutical industry, Incyte

CRANBURY, N.J., Dec. 09, 2022 (GLOBE NEWSWIRE) -- CURE Media Group, the industry-leading multimedia platform devoted to providing cancer updates and research to the more than one million patients, survivors, and caregivers, today announced the recipients of the 2022 MPN Heroes® Recognition Program.

Key Points: 
  • CRANBURY, N.J., Dec. 09, 2022 (GLOBE NEWSWIRE) -- CURE Media Group, the industry-leading multimedia platform devoted to providing cancer updates and research to the more than one million patients, survivors, and caregivers, today announced the recipients of the 2022 MPN Heroes® Recognition Program.
  • “This year marks the tenth anniversary of the MPN Heroes® Recognition Program, and we are honored to recognize these individuals who have made a difference in MPN care.”
    The recipients of the 2022 MPN Heroes® Recognition Program are:
    Mayra D. Andújar Delgado, who is a fierce advocate for patients in the MPN community.
  • For more information on the 2022 MPN Heroes® Recognition Program, click here.
  • Incyte Corporation partners with CURE Media Group to support the program, with CURE® hosting the annual MPN Heroes recognition ceremony.

CMS (867.HK) Joins Hand with Incyte on Ruxolitinib Cream, Brings 1st Repigmentation Drug for Vitiligo Patient

Retrieved on: 
Tuesday, December 6, 2022
Cream, Janus, Woman, JAK, Sclerotherapy, Quality of life, AD, Incidence, Partnership, Atopic dermatitis, Heredity, Autoimmune disease, Marketing, FDA, Safety, Vitiligo, CMS, Skin, Tablet, Dermatology, PD-1, Neck, TCS, Face, Plasma protein binding, Territory, Conditional sentence, Patient, Report, Alopecia areata, Prejudice, Varicose veins, Disease, Ruxolitinib, Patent, FGFR1, Janus kinase 1, Week, TCI, Pharmaceutical industry, Fine chemical, Lancet, Incyte, Novartis, Lilly

Ruxolitinib Cream is the only topical JAK inhibitor and the first vitiligo repigmentation drug approved by the U.S. FDA.

Key Points: 
  • Ruxolitinib Cream is the only topical JAK inhibitor and the first vitiligo repigmentation drug approved by the U.S. FDA.
  • Through this transaction, CMS once again brings a novel treatment option for patients with unmet medical needs.
  • The product was approved by the FDA in July 2022 for the topical non-segmental vitiligo patients.
  • In July this year, Ruxolitinib Cream became the first and only drug approved by the U.S. FDA for vitiligo patients repigmentation.

Incyte to Present at Upcoming Investor Conferences

Retrieved on: 
Thursday, December 15, 2022
Biotechnology, General Health, Pharmaceutical, Health, Therapy, EST, PST, Conference, Incyte

Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of January:

Key Points: 
  • Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of January:
    Goldman Sachs Annual Healthcare CEOs Unscripted Conference: A View from the Top on Thursday, January 5, 2023 at 9:45 am (EST)
    41st Annual J. P. Morgan Healthcare Conference on Monday, January 9, 2023 at 7:30 am (PST)
    The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay.
  • Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics.
  • For additional information on Incyte, please visit Incyte.com and follow @Incyte .
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20221215005007/en/

Incyte’s Novel Mutant CALR Antibody Unveiled at ASH 2022 Plenary Scientific Session

Retrieved on: 
Sunday, December 11, 2022
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Congress, Security (finance), Therapy, Pancreatic serous cystadenoma, BET, Society, Research, 2021 Essex County Council election, Patient, Prevalence, ET, MF, Polycythemia, Ruxolitinib, Disease, FDA, GVHD, COVID-19, Cell, Lymphatic system, Human, JAK2, Bone marrow, Annual report, Safety, University, ALK2, CALR, Doctor of Philosophy, Marketing, ASH, Abstract, Mutation, Graft-versus-host disease, Pharmaceutical industry, Vaccine, Wood drying, Calreticulin, Myeloproliferative neoplasm, Incyte

This research was featured in the Plenary Scientific Session (Abstract #6.

Key Points: 
  • This research was featured in the Plenary Scientific Session (Abstract #6.
  • Session: Hematology Disease Topics & Pathways: Research, Diseases, Therapies, Myeloid Malignancies) at the 64th American Society of Hematology (ASH) Annual Meeting, held December 10-13, 2022, in New Orleans and virtually1.
  • CALR mutations are responsible for disease development in approximately 25-35%2,3 of patients with MF and ET two common types of MPNs.
  • INCA033989 binds with high affinity to mutant CALR and inhibits oncogenesis, the process of cells becoming cancerous, in cells expressing this oncoprotein.

CURE Media Group announces Vanessa Bayer as keynote speaker for the 2022 MPN Heroes® Recognition Program 

Retrieved on: 
Friday, December 2, 2022
Therapy, The National WWII Museum, Bayer, Pancreatic serous cystadenoma, Survivor, MPN, Leukemia, Season, Patient, The National, CURE, Cancer, Dream, University, Friends, Motivation, Research, Caregiver, Education, Organization, Pharmaceutical industry, Incyte

CRANBURY, N.J., Dec. 02, 2022 (GLOBE NEWSWIRE) -- CURE Media Group, the industry-leading multimedia platform devoted to providing cancer updates and research to the more than one million patients, survivors, and caregivers, today announced Emmy-nominated actress, writer and comedian Vanessa Bayer as the keynote speaker of the 2022 MPN Heroes Recognition Program.

Key Points: 
  • CRANBURY, N.J., Dec. 02, 2022 (GLOBE NEWSWIRE) -- CURE Media Group, the industry-leading multimedia platform devoted to providing cancer updates and research to the more than one million patients, survivors, and caregivers, today announced Emmy-nominated actress, writer and comedian Vanessa Bayer as the keynote speaker of the 2022 MPN Heroes Recognition Program.
  • We are truly delighted that Vanessa Bayer will join us to deliver the keynote address at this years MPN Heroes recognition ceremony, said Mike Hennessy Jr., president and CEO of MJH Life Sciences, the parent company of CURE Media Group.
  • The recipients of the 2022 MPN Heroes Recognition Program, who have made a significant impact in the MPN blood cancer community, will be announced at the event.
  • Incyte Corporation partners with CURE Media Group to support the program, with CURE hosting the annual MPN Heroes recognition ceremony.